文献速递前列腺癌

基于PSMA PET/CT与mpMRI的前列腺癌无活检根治术决策算法

Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-01-31

本研究提出并评估一种基于PSMA PET/CT和mpMRI的决策算法,用于筛选适合直接行根治性前列腺切除术(RP-WPB)的患者。2022年1月至2024年2月共前瞻性入组150例,120例接受RP-WPB,临床显著前列腺癌(csPCa,ISUP≥2)检出率100%(95%CI 0.97-1.00,p=0.176),病理一致性好,无Clavien-DindoⅡ级以上并发症。

要点

  • 算法要求PSA>4 ng/mL、PI-RADS≥4、miPSMA≥2且mpMRI与PSMA PET/CT共同阳性。
  • cT2N0M0且PSA 4-30 ng/mL者可入组前瞻研究,PSA≥30者需附加条件。
  • 120例RP-WPB中csPCa检出率100%,无严重围手术期并发症。

核心结论

  • 基于PSMA PET/CT和mpMRI的RP-WPB决策算法安全、可行且诊断准确性高。

研究设计与样本

  • 前瞻性研究,2022年1月至2024年2月按预设算法入组150例,120例接受RP-WPB。

主要发现

  • 120例中cT2N0M0 84例、cT3-4 27例、cN1 10例、cM1 9例。
  • csPCa(ISUP≥2)检出率100%(95%CI 0.97-1.00,p=0.176),全部病例病理一致。
  • 无Clavien-DindoⅡ级以上围手术期并发症。

关键数值与推荐

  • RP-WPB候选需满足:PSA>4 ng/mL、PI-RADS≥4、miPSMA≥2、mpMRI与PSMA PET/CT共同阳性。
  • cT3-4、cN1或cM1(孤立转移)可直接行RP-WPB。
  • cT2N0M0且PSA 4-30 ng/mL可入前瞻研究;PSA≥30 ng/mL需年龄≥75岁、PSAD≥0.2 ng/mL/cm3且愿意接受非神经血管束保留手术。

临床怎么用

  • 对符合四要素且影像共同阳性的选定患者,可考虑免活检直接行根治性前列腺切除术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent advancements in radiological imaging have raised the possibility of diagnosing prostate cancer (PCa) without biopsy; however, the safety, feasibility, and diagnostic accuracy of this approach require comprehensive evaluation. This study proposes and evaluates an initial decision-making algorithm using PSMA PET/CT and mpMRI for selecting candidates suitable for radical prostatectomy without prior biopsy (RP-WPB). METHODS: Patient enrollment was conducted strictly according to the prospectively established decision-making algorithm. Candidates for RP-WPB were required to fulfill four essential criteria: PSA > 4 ng/mL, PI-RADS score≥4, miPSMA score≥2, and co-positive lesions identified on mpMRI and PSMA PET/CT. Patients staged as cT3-4, cN1, or cM1 (solitary metastasis) underwent RP-WPB directly. For patients with stage cT2N0M0, PSA levels were further stratified: those with PSA ranging from 4 to 30 ng/mL were invited to participate in the prospective study, whereas individuals with PSA ≥ 30 ng/mL qualified for RP-WPB only if they satisfied additional conditions, including age≥75 years, PSA density (PSAD) ≥ 0.2 ng/mL/cm3, and willingness to undergo non-neurovascular-bundle-sparing surgery. RESULTS: From January 2022 to February 2024, 150 patients were prospectively enrolled following the algorithm; 30 patients withdrew, and 120 underwent RP-WPB. Among the latter, 84 patients were classified as cT2N0M0, 27 as cT3-4, 10 as cN1, and 9 as cM1. The detection rate of clinically significant PCa (csPCa) (ISUP grade ≥2) patients was 100% (95% CI: 0.97-1.00, p = 0.176), and pathological concordance was achieved in all cases. No perioperative complications greater than Clavien-Dindo grade Ⅱ occurred. CONCLUSIONS: The proposed algorithm based on PSMA PET/CT and mpMRI for performing RP-WPB demonstrates safety, feasibility, and high diagnostic accuracy, presenting a promising option for selected PCa patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Li Z, Luo J, Liu Q, et al. Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI. Prostate Cancer Prostatic Dis. 2026. PMID: 41620496. doi:10.1038/s41391-026-01081-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。